Navigation Links
ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
Date:6/3/2008

Compound Emerged from Technology Licensed from Schering-Plough Research

Institute

ROCKVILLE, Md., June 3 /PRNewswire-FirstCall/ -- ViroDefense Inc today announced that it has chosen to advance a compound licensed to ViroDefense Inc by Schering-Plough Corporation into IND-enabling preclinical studies for the prevention and treatment of poliovirus infections.

Schering-Plough licensed to ViroDefense Inc the exclusive rights for development of a specific compound series for polio indications. The license was provided in exchange for the purchase of compound testing supplies and potential future royalties on sales. Schering-Plough Research Institute had been developing the series for treatment of diseases caused by non-polio enteroviruses, such as the coxsackie viruses. ViroDefense Inc determined in laboratory tests that compounds of the series had promising anti-poliovirus activity.

The licensed compounds belong to the antiviral mechanistic class termed "capsid inhibitors." Compounds of this class inhibit the function of the poliovirus capsid, the outer protein coat of the virus, by integrating into the capsid at a specific site or pocket. By doing so, they prevent virus "uncoating" and the release of the viral RNA from the capsid, thereby blocking the initiation of the viral infection cycle.

The lead anti-poliovirus compound, V-073, has been shown to have potent and broad-spectrum anti-poliovirus specific activity, favorable pharmacologic and pharmacokinetic attributes, and the safety and tolerability profile suitable for its advancement as a preclinical candidate. Consequently, IND- enabling studies will commence with V-073.

"We are grateful to Schering-Plough for their willingness to offer this promising antiviral series for the fight against polio," commented Marc S. Collett, President of ViroDefense Inc. "This is clearly a humanitarian gesture on their part."

"We are very pleased to s
'/>"/>

SOURCE ViroDefense Inc
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
2. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
3. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
4. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
5. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
6. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
7. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
8. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
11. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...30 Decision Resources, one of the ...ng on pharmaceutical and healthcare issues, foreca...ia will grow nine percent annually over the 2008 -... This growth will be driven mainly by increased go...of more-expensive therapies like pegylated interfe...
(Date:11/30/2009)...30 The U.S. Food and Dru... (duloxetine HCl) for the maintenance treatment of... Lilly and Company (NYSE: LLY ) announced today....a chronic illness, it is important that doctors an...ffective in both the acute and maintenance phase o...
(Date:11/30/2009)...30 Sanofi-aventis U.S. a...ng agreement with Intelliject, Inc. for a novel ep...t of allergic reactions (anaphylaxis) in North Ame...have this opportunity to offer this innovative del... risk of this life-threatening allergic reaction e...
Breaking Medicine Technology:Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 2Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 2FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 4FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 5Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America 2Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America 3DopeStats com Provides Statistics on Oxycodone Abused in Non Medical Purposes 61912 1DopeStats com Provides Statistics on Oxycodone Abused in Non Medical Purposes 61912 2Tis the Season to Eat and Eat More 21 61910 1Tis the Season to Eat and Eat More 21 61910 2New research shows versatility of amniotic fluid stem cells 61908 1New research shows versatility of amniotic fluid stem cells 61908 2
....Va., May 27 The Blanchette Rockefeller Neuroscie...tions, Inc. (Inverness, NYSE: IMA ) of Waltham, M... and health management, announced today that they ...alize a diagnostic test for Alzheimer,s disease fi...RNI test, once fully commercialized, could dramati...
...., May 26 Theranostics Health, Inc. (TH) is pleas...ical research study funded by the Susan G. Komen F...was the recipient of a Promise Grant, part of over...09 to further the development of new prevention an...san G. Komen for the Cure(R) is a nonprofit organi...
Other Medicine Technology:Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease 2Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease 3Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease 4Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R) 2Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R) 3
(Date:11/30/2009)... , SILVER SPRING, Md., Nov. 30 /PRNewsw...se consumers a bronzed body year-round, but the ul...serious health risks. ,, (Logo: http://www.ne...Although some people think that a tan gives them a..." says Sharon Miller, M.S.E.E., a Food and Drug Ad...
(Date:11/30/2009)... , NASHVILLE, Tenn., Nov. 30 /PRNewswire...ng about gifts for the holidays. For a loved one w... family members and friends oftentimes struggle wi... Living , one of the leading providers of senior l...er,s and dementia care , offers these suggestions....
(Date:11/30/2009)... , PHILADELPHIA, ...- , - Exclusive Updates From Elsevier,s T...eform and ARRA Momentum , Elsevier, a wor...s well,as web-based and electronic health record (...nline resource center for American Recovery and Re...
(Date:11/30/2009)...he European Association of Urology (EAU) and Europ...ght against prostate cancer, have entered into an,... commitment to increase and improve,patient aware...., Professor Per-Anders Abrahamsson, Secretary-G...iliated partnership, Europa Uomo will gain access ...
(Date:11/30/2009)...CAGONovember 30, 2009A pet owner knows the enormou...cially in troubled times. Most pets are considered... companions. A growing body of research now docume...velopment, elderly care, mental illness, physical ...nd the rehabilitation of incarcerated youth and ad...
Breaking Medicine News(10 mins):Health News:Gift Ideas for Loved Ones with Alzheimer's/Dementia 2Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 2Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 3Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 4Health News:The therapeutic benefits of the human-animal bond 2
...w business development of its ULTRA lo... Iowa, May 1 Asoyia has finalized an,agreement wi...ion to expand,marketing, research and development ...soybean oils with the highest,level of stability a...
...ewhere report what is believed to be the first wid...onged inflammation of heart tissue and the subsequ...umping organ. , The latest findings from the Mult...yet one more reason for the estimated 72 million o...
...cal,companies and CROs agree that effective clinic...l path in successful clinical trials and subsequen...cience and Art of Winning,Investigators in a Compe...mplimentary report summary, including sample best,...
... SHP, NASDAQ: SHPGY), the global specialty biophar...resent key scientific data on its Attention Defici...amfetamine dimesylate, methylphenidate transdermal...nnual meeting to be held May 3rd to 8th in Washing...
...icated to influencing children,s eat...1 In celebration of its 35th,anniversary, the Whe...rom,Parents to Children, an educational cookbook f...s.org, showcases,wheat-based recipes and addresse...
...nic in North Carolina, CDC says , , THURS...eived derriere-enhancing injections at an unlicens...re after the procedure. , Not only was the facilit...actly, was in the injections. , All three women su...
Other Medicine News:Health News:Asoyia Secures Venture Capital Funding 2Health News:Asoyia Secures Venture Capital Funding 3Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 2Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 3Health News:Strategies for Winning Clinical Investigators in a Competitive Marketplace 2Health News:Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting 2Health News:Parents Can Educate Kids in the Kitchen With Cookbook from Chef Gale Gand and Wheat Foods Council 2Health News:3 Women Suffer Kidney Failure After Derriere Injections 2Health News:3 Women Suffer Kidney Failure After Derriere Injections 3Health News:3 Women Suffer Kidney Failure After Derriere Injections 4
...ly 1990s, the "Reversed" shoulder prosthesis has b...success. More recently, an ever-growing number of ...on this prosthesis and the associated surgical tec...is the result of nearly fifteen years of clinical ...
AMINCO-Bowman Series 2 (AB2) Spectrofluorometer
SPEX Fluorolog-3
Gemini XPS Microplate Spectrofluorometer
Medicine Products: